Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.53 |
| ▸ | F9 | P00740 | 4/20 | 0.53 |
| ▸ | F7 | P08709 | 3/20 | 0.53 |
| ▸ | F11 | P03951 | 3/20 | 0.53 |
| ▸ | PLAU | P00749 | 8/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.51 |
| ▸ | F2 | P00734 | 8/20 | 0.49 |
| ▸ | PLG | P00747 | 7/20 | 0.49 |
| ▸ | PLAT | P00750 | 6/20 | 0.49 |
| ▸ | HPN | P05981 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975521 | 0.92 | F10 (0.63) | F10F9F7F11PLAU | |
| SCHEMBL7982567 | 0.92 | F10 (0.58) | F10F9F7F11PLAU | |
| SCHEMBL10140745 | 0.91 | F10 (0.46) | F10F9F7F11PLAU | |
| SCHEMBL10140709 | 0.90 | F10 (0.48) | F10F9F7F11PLAU | |
| SCHEMBL10139884 | 0.90 | F10 (0.48) | F10F9F7F11PLAU | |
| SCHEMBL7974724 | 0.90 | F10 (0.47) | F10F9F7F11PLAU | |
| SCHEMBL10140114 | 0.88 | F10 (0.47) | F10F9F7F11PLAU | |
| SCHEMBL10139941 | 0.87 | F7 (0.46) | F10F9F7F11PLAU | |
| SCHEMBL10139900 | 0.84 | F10 (0.46) | F10F9F7F11PLAU | |
| SCHEMBL7960525 | 0.84 | F10 (0.56) | F10F9F7F11PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-B1 | Heterocyclic compounds as factor IXA inhibitors. | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | F10 11/4885F9 1/4885F7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.